Value
9.4/10data confidence 50%| Component | Sub-score |
|---|---|
| P/S | 9.1 |
| Fwd P/E | 9.2 |
| PEG | 10.0 |
- ▸Forward P/E: 10.4x
- ▸PEG: 0.05
- ▸Attractively valued
ARDX · Why this verdict
Why Ardelyx (ARDX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.2/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Ardelyx is a fast-growing biotech (24% revenue growth, forward P/E 10.4x) that is down 64% from its high in a confirmed downtrend, with single-product concentration, insider selling and earnings in 2 days; it is a speculative recovery with an unreliable analyst target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is growing 24% year over year, with earnings growth scoring a perfect 10 and the stock valued at a forward P/E of 10.4x. Growth breakdown | Revenue growth stays above 20% and the company moves toward GAAP profitability. | →Stable |
| CounterEarnings misses (-41% in August) and a GAAP loss show the growth has not yet translated into reliable profits. | ||
The business depends on a single product, IBSRELA, and carries a high-severity concentration risk, so one product setback could dominate results. Bear case | Revenue diversification improves or the lead product keeps growing at 20% or more. | ↑Improving |
| CounterConcentration in a growing approved product is normal for a commercial-stage biotech and is the source of the growth. | ||
Price is below the 200-day average with a -7.4%/30d slope and a death cross, 64% below its 52-week high. Momentum breakdown | Price reclaims the 200-day average and momentum rises above 4.5. | ↓Deteriorating |
| CounterInstitutions are accumulating and OBV is rising, which can precede a reversal after a deep drawdown. | ||
Insiders made 21 sales totaling $486K over 90 days with no purchases, and leverage (debt-to-equity 1.9) adds a penalty. Insider | Insider selling stops and debt-to-equity declines below 1.5. | →Stable |
| CounterThe selling is only 0.062% of market cap, so it is minor and may be routine. | ||
The raw analyst target of $12.80 is 4.2x the $3.03 price and was rejected as implausible, so the claimed 322% upside cannot be relied on and no target upside is credited. Warnings | Analyst targets converge to a credible range within 100% of price after the November 3 report. | ↑Improving |
| CounterBiotech targets can legitimately sit far above price if approvals or sales inflect, so a rejected target is not proof the upside is false. | ||
Revenue is growing 24% year over year, with earnings growth scoring a perfect 10 and the stock valued at a forward P/E of 10.4x.
→StableGrowth breakdown
- Expectation
- Revenue growth stays above 20% and the company moves toward GAAP profitability.
CounterEarnings misses (-41% in August) and a GAAP loss show the growth has not yet translated into reliable profits.
The business depends on a single product, IBSRELA, and carries a high-severity concentration risk, so one product setback could dominate results.
↑ImprovingBear case
- Expectation
- Revenue diversification improves or the lead product keeps growing at 20% or more.
CounterConcentration in a growing approved product is normal for a commercial-stage biotech and is the source of the growth.
Price is below the 200-day average with a -7.4%/30d slope and a death cross, 64% below its 52-week high.
↓DeterioratingMomentum breakdown
- Expectation
- Price reclaims the 200-day average and momentum rises above 4.5.
CounterInstitutions are accumulating and OBV is rising, which can precede a reversal after a deep drawdown.
Insiders made 21 sales totaling $486K over 90 days with no purchases, and leverage (debt-to-equity 1.9) adds a penalty.
→StableInsider
- Expectation
- Insider selling stops and debt-to-equity declines below 1.5.
CounterThe selling is only 0.062% of market cap, so it is minor and may be routine.
The raw analyst target of $12.80 is 4.2x the $3.03 price and was rejected as implausible, so the claimed 322% upside cannot be relied on and no target upside is credited.
↑ImprovingWarnings
- Expectation
- Analyst targets converge to a credible range within 100% of price after the November 3 report.
CounterBiotech targets can legitimately sit far above price if approvals or sales inflect, so a rejected target is not proof the upside is false.
Per-dimension breakdown
Quality
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.7 |
| FCF quality | 3.9 |
| Moat | 5.8 |
| Rule of 40 | 5.5 |
| Piotroski F | 5.6 |
- ▸FCF-positive despite GAAP loss (FCF margin 5%, FCF yield 2.6%)
Growth
9.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 8.4 |
| EPS growth | 10.0 |
- ▸Strong growth: 24% YoY
Momentum
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 6.2 |
| OBV | 1.5 |
| MA position | 1.0 |
| Volume | 1.5 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -7.7%/30d — confirmed downtrend
Sentiment
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.5 |
| Analyst rating | 8.2 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.50 (n=1)
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 320%
Insider
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider selling — $486,197 (0.062% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 9.5 |
| quality rank | 3.8 |
| growth rank | 5.9 |
Technical
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.4 |
| support resistance | 7.8 |
| 52w position | 0.0 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.0 |
| days to cover | 3.7 |
| volatility | 2.1 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 8.4 |
| debt equity | 3.2 |
- ▸High IV: 99%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings today
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (3)
- INSIDER:OK
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- MOMENTUM:2.9<4.5
- DEATH_CROSS:HARD_BLOCK
- EARNINGS_PROXIMITY:0d<=7d
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+7.7%
Downside
8.3%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 42
EdgeInst Constrain — Small cap ($0.8B) below institutional reach
SuitabilitySpeculative — Drawdown -64% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Value at 9.4) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:2.9<4.5, DEATH_CROSS:HARD_BLOCK, EARNINGS_PROXIMITY:0d<=7d) reinforce the read. Current asymmetry R:R is 0.00 — supplementary context, not the trigger for this path.
The strongest dimensions are Value at 9.4, Growth at 9.2, and Sentiment at 8.5; the weakest are Momentum at 2.9, Catalyst at 3.0, and Quality at 4.0. The V9 engine flagged 3 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Revenue Growth
Trip ifRevenue growth falls below 10% year over year.
- P2Product Concentration Risk
Trip ifLead product share of revenue rises above 90%.
- P3Confirmed Downtrend
Trip ifPrice falls below the 200-day average by more than 20%.
- P4Insider Selling And Leverage
Trip ifInsider selling exceeds $2M over a 90-day window.
- P5Unreliable Analyst Target
Trip ifConsensus analyst target falls below the current $3.03 price.